BOSTON & BRUSSELS--(BUSINESS WIRE)--Neutron Therapeutics, Inc (NT) and the University Hospital of Brussels (H.U.B) today announced that they have signed a Letter of Intent to place a nuBeam® suite for Boron-Neutron Capture Therapy (BNCT) at the Institut Jules Bordet (IJB), Erasmus Campus, Anderlecht. nuBeam® is the world’s safest and most powerful accelerator-based neutron source designed specifically for the hospital environment. With this agreement, H.U.B will become the third clinical center in the world to implement NT's ground-breaking technology, enabling new therapeutic options for cancer patients.

BNCT is an emerging, biologically-targeted form of radiotherapy that destroys tumor cells with minimal impact to surrounding healthy cells. It has the potential to revolutionize radiation oncology, having demonstrated compelling success in some of the most difficult-to-treat cancers and in treating patients for whom all other treatment options have been exhausted.

H.U.B and NT have entered into an agreement whereby NT will deliver to H.U.B a complete nuBeam® BNCT treatment suite consisting of an accelerator-based neutron source and ancillary systems. The nuBeam® solution incorporates OncologyOne software developed by Cosylab, a proven partner with over two decades of experience solving complex software challenges in radiation therapy. To further develop BNCT into a mainstream therapeutic modality, NT and H.U.B will collaborate on research and development of BNCT technology through pre-clinical and clinical studies in a range of cancer indications with high unmet need.
Renaud Witmeur, CEO of H.U.B stated, “As a pioneering center in the fight against cancer, H.U.B via Jules Bordet Institute (Belgian reference center in oncology) has a patient-centered vision built around three core pillars: research, teaching and innovation. The partnership we have just signed fits perfectly into this strategy by offering a new and very promising therapeutic solution to our patients.”

Neutron Therapeutic’s nuBeam® Suite is a high-throughput, compact accelerator-based neutron source suitable for clinical settings. nuBeam® replaces legacy nuclear reactors, offering the highest neutron flux of all currently available BNCT systems, and is the only device capable of producing an IAEA-compliant BNCT beam for the safe and effective clinical use of neutrons. With roots in technology originating from Massachusetts Institute of Technology (MIT), nuBeam® is the result of years of R&D effort by NT’s technology team, enabling unparalleled efficiency, reliability, serviceability and neutron beam quality.

Rad Oncology Homepage